Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Switzerland

Marie Skłodowska-Curie Action · Running

MODIFy Multi-Omic study of transcription factor Dose-Induced cell Fate

Coordinator
Ecole Polytechnique Federale De Lausanne, Switzerland
Runs
1 July 2026 to 30 June 2028
Status
Running
EU funding
€292k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101272449

What the project is doing

In the project's own words, from its summary on CORDIS.

MODIFy (Multi-Omic study of transcription factor Dose-Induced cell Fate) is a multimodal experimental and computational project aimed at dissecting the interplay between human genetic variability and transcription factor (TF) dose in the context of human induced pluripotent stem cell (hiPSC) differentiation. Transcription factors (TFs) establish a cell’s gene expression profile, and their overexpression can induce cell state and even cell identity changes such as reprogramming of human somatic cells into hiPSCs. hiPSCs can then be differentiated into specific cell types for therapeutic purposes.

However, hiPSC differentiation is highly heterogeneous and inefficient. This is due to molecular complexities including variability in the expression levels of the inducing TFs and differences in pluripotency among hiPSC lines, which can be driven by genetic variation. MODIFy aims to dissect the determinants of hiPSC differentiation heterogeneity by studying the interplay between TF expression level (dose) and genetic background at the single cell level.

To this end, I will build on scTF-seq, a method developed in the Deplancke lab that enables systematic assessment of TF-induced cell state transitions across a wide dose range with single cell RNA sequencing (scRNA-seq). I will extend scTF-seq by incorporating a multimodal readout that combines transcriptomic and chromatin accessibility profiling, and apply it to genetically different hiPSC lines. This will allow me to decipher the gene regulatory networks activated at different TF doses and uncover how genetic variation influences them by modulating TF dose sensitivity.

By combining my experience in in vitro differentiation, method development and bioinformatics with the expertise of Prof. Deplancke’s lab in scRNA-seq this project will yield fundamental insights into how TF dose and genotype interact to control cell fate,ultimately guiding improved strategies for cell engineering across diverse human genetic background.

Topics

Who is involved

OrganisationCityCountryRole
Ecole Polytechnique Federale De LausanneLausanneSwitzerlandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI